Sampo's Board has approved a EUR 350 million share buyback program, repurchasing up to 45 million shares or 1.69% of total shares. The buyback, starting May 7 and ending by October 30, 2026, is funded by 2025 operating results and recent asset sales. Shares will be bought on multiple exchanges and possibly via accelerated bookbuilds, with the goal to reduce capital by cancelling repurchased shares. The company may increase the program if further capital is freed from asset disposals, signaling a commitment to strong capital returns and balance sheet efficiency.
The Rosen Law Firm is investigating claims that the Flow Foundation provided misleading business information to FLOW cryptocurrency investors. Investors who bought FLOW on or before December 27, 2025, and held it through December 29, 2025, may be eli...
Over five trading days from August 3 to 7, US spot Bitcoin ETFs attracted $853.5 million in net inflows, with BlackRock's iShares Bitcoin Trust (IBIT) accounting for $693 million, or 81% of the total. This inflow reversed the previous week's $61.5 mi...
The Rosen Law Firm has announced an investigation into potential breaches of fiduciary duties by the directors and officers of Manhattan Associates, Inc. This legal action is significant for investors as it may impact the company's governance and sto...
The JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) combines large-cap Nasdaq stocks with a covered-call strategy to provide monthly income and reduce volatility. It offers a high trailing distribution rate of about 10.9%, which increases during mar...
EyePoint Pharmaceuticals is approaching a critical valuation point with upcoming Phase III LUGANO trial results for its DURAVYU treatment targeting wet age-related macular degeneration (AMD), expected by August 2026. The trial focuses on sustained si...
